DK3463436T3 - Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling - Google Patents
Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling Download PDFInfo
- Publication number
- DK3463436T3 DK3463436T3 DK17729078.0T DK17729078T DK3463436T3 DK 3463436 T3 DK3463436 T3 DK 3463436T3 DK 17729078 T DK17729078 T DK 17729078T DK 3463436 T3 DK3463436 T3 DK 3463436T3
- Authority
- DK
- Denmark
- Prior art keywords
- vaccine
- cancer
- treatment
- combination
- immune checkpoint
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16172760 | 2016-06-02 | ||
| PCT/EP2017/063589 WO2017207814A1 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3463436T3 true DK3463436T3 (da) | 2023-12-18 |
Family
ID=56132759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17729078.0T DK3463436T3 (da) | 2016-06-02 | 2017-06-02 | Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11419927B2 (https=) |
| EP (2) | EP4253419A3 (https=) |
| JP (2) | JP7321709B2 (https=) |
| AU (1) | AU2017275782B2 (https=) |
| CA (1) | CA3026172A1 (https=) |
| CY (1) | CY1126489T1 (https=) |
| DK (1) | DK3463436T3 (https=) |
| ES (1) | ES2965957T3 (https=) |
| FI (1) | FI3463436T3 (https=) |
| HR (1) | HRP20231650T1 (https=) |
| HU (1) | HUE065176T2 (https=) |
| LT (1) | LT3463436T (https=) |
| PL (1) | PL3463436T3 (https=) |
| PT (1) | PT3463436T (https=) |
| RS (1) | RS65007B1 (https=) |
| SI (1) | SI3463436T1 (https=) |
| WO (1) | WO2017207814A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2536830T3 (pl) | 2010-02-16 | 2020-02-28 | Ultimovacs As | Polipeptydy |
| EP4253419A3 (en) | 2016-06-02 | 2024-05-22 | Ultimovacs ASA | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| GB201803178D0 (en) * | 2018-02-27 | 2018-04-11 | Univ Oslo Hf | Specific binding molecules for htert |
| TWI805792B (zh) * | 2018-06-29 | 2023-06-21 | 日商大鵬藥品工業股份有限公司 | 抗腫瘤劑及其評估方法 |
| US20250152688A1 (en) | 2021-06-09 | 2025-05-15 | Ultimovacs Ab | A Conjugate |
| WO2024083866A1 (en) | 2022-10-17 | 2024-04-25 | Ultimovacs Asa | Cancer treatment |
| WO2024126758A2 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A nucleic acid molecule and a chimeric polypeptide |
| WO2024126737A1 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A core and a conjugate |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5004390B2 (ja) | 1999-08-23 | 2012-08-22 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 新規ｂ７−４分子およびその用途 |
| DK1234031T3 (en) | 1999-11-30 | 2017-07-03 | Mayo Foundation | B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE |
| NZ536420A (en) | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2536830T3 (pl) | 2010-02-16 | 2020-02-28 | Ultimovacs As | Polipeptydy |
| LT2547364T (lt) | 2010-03-15 | 2017-03-27 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Peptidai, konjugatai ir vakcinos imunogeniškumo padidinimo būdas |
| WO2012037551A2 (en) | 2010-09-17 | 2012-03-22 | Irx Therapeutics, Inc. | Primary cell-derived biologic and wt1 synthetic long peptide vaccine |
| US9561266B2 (en) | 2012-08-31 | 2017-02-07 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
| GB201223386D0 (en) | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| US9974845B2 (en) * | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
| KR20150130284A (ko) | 2013-03-15 | 2015-11-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 백신 및 이를 이용한 치료 방법 |
| GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| US20170035864A1 (en) | 2013-12-09 | 2017-02-09 | Bullet Biotechnology, Inc. | SPECIFIC VIRUS-LIKE PARTICLE-CpG OLIGONUCLEOTIDE VACCINES AND USES THEREOF |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| WO2015096811A1 (zh) | 2013-12-27 | 2015-07-02 | 厦门松霖科技有限公司 | 暗装预埋组件 |
| ES2738582T3 (es) | 2014-02-14 | 2020-01-23 | Immune Design Corp | Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica |
| WO2015128313A1 (en) | 2014-02-25 | 2015-09-03 | Deutsches Krebsforschungszentrum | Rna viruses for immunovirotherapy |
| KR102499737B1 (ko) | 2014-05-13 | 2023-02-13 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법 |
| ES2851451T3 (es) | 2014-05-13 | 2021-09-07 | Bavarian Nordic As | Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3 |
| US20170136127A1 (en) | 2014-07-01 | 2017-05-18 | Vicus Therapeutics, Llc | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them |
| EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| CA2954279C (en) | 2014-07-07 | 2023-11-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| EP3169355A4 (en) | 2014-07-18 | 2018-07-25 | Advaxis, Inc. | Listeria-based immunogenic compositions for eliciting anti-tumor responses |
| US10759836B2 (en) | 2014-07-18 | 2020-09-01 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
| WO2016025647A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| WO2016063263A2 (en) | 2014-10-23 | 2016-04-28 | Institut Gustave Roussy | Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
| US11236139B2 (en) | 2014-11-05 | 2022-02-01 | The Regents Of The University Of California | Combination immunotherapy |
| MX2018008797A (es) | 2016-01-19 | 2018-11-29 | Pfizer | Vacunas contra el cancer. |
| EP4253419A3 (en) | 2016-06-02 | 2024-05-22 | Ultimovacs ASA | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
-
2017
- 2017-06-02 EP EP23178501.5A patent/EP4253419A3/en active Pending
- 2017-06-02 RS RS20231231A patent/RS65007B1/sr unknown
- 2017-06-02 JP JP2018563076A patent/JP7321709B2/ja active Active
- 2017-06-02 HR HRP20231650TT patent/HRP20231650T1/hr unknown
- 2017-06-02 SI SI201731461T patent/SI3463436T1/sl unknown
- 2017-06-02 US US16/306,352 patent/US11419927B2/en active Active
- 2017-06-02 FI FIEP17729078.0T patent/FI3463436T3/fi active
- 2017-06-02 ES ES17729078T patent/ES2965957T3/es active Active
- 2017-06-02 AU AU2017275782A patent/AU2017275782B2/en not_active Ceased
- 2017-06-02 CA CA3026172A patent/CA3026172A1/en active Pending
- 2017-06-02 LT LTEPPCT/EP2017/063589T patent/LT3463436T/lt unknown
- 2017-06-02 HU HUE17729078A patent/HUE065176T2/hu unknown
- 2017-06-02 PL PL17729078.0T patent/PL3463436T3/pl unknown
- 2017-06-02 WO PCT/EP2017/063589 patent/WO2017207814A1/en not_active Ceased
- 2017-06-02 PT PT177290780T patent/PT3463436T/pt unknown
- 2017-06-02 DK DK17729078.0T patent/DK3463436T3/da active
- 2017-06-02 EP EP17729078.0A patent/EP3463436B1/en active Active
-
2022
- 2022-08-09 US US17/818,584 patent/US12168045B2/en active Active
- 2022-08-24 JP JP2022132995A patent/JP2022171684A/ja active Pending
-
2023
- 2023-12-19 CY CY20231100756T patent/CY1126489T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3463436T (pt) | 2023-12-28 |
| CA3026172A1 (en) | 2017-12-07 |
| US12168045B2 (en) | 2024-12-17 |
| JP7321709B2 (ja) | 2023-08-07 |
| EP4253419A2 (en) | 2023-10-04 |
| EP3463436B1 (en) | 2023-09-20 |
| CY1126489T1 (el) | 2026-02-25 |
| LT3463436T (lt) | 2024-01-25 |
| AU2017275782B2 (en) | 2024-08-15 |
| HRP20231650T1 (hr) | 2024-05-10 |
| US11419927B2 (en) | 2022-08-23 |
| RS65007B1 (sr) | 2024-01-31 |
| EP4253419A3 (en) | 2024-05-22 |
| EP3463436A1 (en) | 2019-04-10 |
| HUE065176T2 (hu) | 2024-05-28 |
| US20230049012A1 (en) | 2023-02-16 |
| US20190247482A1 (en) | 2019-08-15 |
| JP2019517508A (ja) | 2019-06-24 |
| SI3463436T1 (sl) | 2024-02-29 |
| FI3463436T3 (fi) | 2023-12-04 |
| ES2965957T3 (es) | 2024-04-17 |
| WO2017207814A1 (en) | 2017-12-07 |
| PL3463436T3 (pl) | 2024-03-04 |
| AU2017275782A1 (en) | 2019-01-24 |
| JP2022171684A (ja) | 2022-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286282A (en) | Use of palinabolin in combination with immune checkpoint inhibitors | |
| IL279752B (en) | Polycyclic compounds and use thereof in the treatment of immune disorders | |
| HUE053763T2 (hu) | Immunellenõrzésipont-gátlók véreredetû rákok kezelésében történõ alkalmazásra | |
| IL258955A (en) | Compositions and methods for treatment of cancer | |
| SI3368069T1 (sl) | Uporaba zaviralcev miostatina in kombinirane terapije | |
| IL265274A (en) | Combined treatment of antibody and checkpoint inhibitor | |
| DK3500299T3 (da) | Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer | |
| DK3463436T3 (da) | Vaccine i kombination med en immuncheckpoint-hæmmer til anvendelse i cancerbehandling | |
| IL245219B (en) | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor | |
| HUE059662T2 (hu) | Eljárás terápiás immunsejtek hatékonyságának fokozására | |
| DK3277842T3 (da) | Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| IL251759B (en) | Compositions and methods for treating insomnia | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| DK3374497T3 (da) | Modificerede makrofager til anvendelse i behandlingen af kræft | |
| IL251904B (en) | Apilimod for use in the treatment of melanoma | |
| HUE058314T2 (hu) | Pridopidin alkalmazása Rett-szindróma kezelésére | |
| HUE053927T2 (hu) | Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra | |
| SI3370733T1 (sl) | Postopek za aktivacijo CD40 in blokada imunske nadzorne točke | |
| IL247435A0 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| CY2024037I2 (el) | Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων | |
| IL256181A (en) | Means and methods for treatment of b-cell malignancies | |
| IL251345A0 (en) | Compositions for use in the treatment of peri-implantitis | |
| DK3125885T3 (da) | Kombination af egfr-inhibitor og mek-inhibitor til anvendelse til behandling af nras-muteret cancer | |
| HUE058645T2 (hu) | Gyógyszer köszvény kezelésében való felhasználásra |